pyridoxamine has been researched along with Diabetic Cardiomyopathies in 1 studies
Diabetic Cardiomyopathies: Diabetes complications in which VENTRICULAR REMODELING in the absence of CORONARY ATHEROSCLEROSIS and hypertension results in cardiac dysfunctions, typically LEFT VENTRICULAR DYSFUNCTION. The changes also result in myocardial hypertrophy, myocardial necrosis and fibrosis, and collagen deposition due to impaired glucose tolerance.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Moore, CJ | 1 |
| Shao, CH | 1 |
| Nagai, R | 1 |
| Kutty, S | 1 |
| Singh, J | 1 |
| Bidasee, KR | 1 |
1 other study available for pyridoxamine and Diabetic Cardiomyopathies
| Article | Year |
|---|---|
Malondialdehyde and 4-hydroxynonenal adducts are not formed on cardiac ryanodine receptor (RyR2) and sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA2) in diabetes.
Topics: Aldehydes; Animals; Arginine; Calcium; Cyclic N-Oxides; Diabetes Mellitus, Experimental; Diabetic Ca | 2013 |